Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:

NCT ID: NCT03017690 Not yet recruiting - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumor

Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Start date: January 2017
Phase: N/A
Study type: Observational

An observational time and motion study in a clinical oncology setting is utilized in order to measure and compare product attributes and overall product efficiency between lanreotide and octreotide LAR.

NCT ID: NCT03014297 Not yet recruiting - Clinical trials for Neuroendocrine Tumors

Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression

Start date: January 2017
Phase: Phase 1
Study type: Interventional

This is a single center, open label, phase I study involving grade I-III gastroenteropancreatic neuroendocrine tumors, consisting of a dose escalation Part A followed by an expansion cohort Part B. On Part A Patients will be treated with daily oral everolimus. Fosbretabulin will be administered IV either q3 weekly or q weekly based on PO CRM cohort. Part B: Once the investigators have established an MTD in Part A, the investigators will be treating 15 more patients at that dose combination. The primary and secondary objectives of the expansion cohort will be similar to Part A of the study, i.e., to establish a safety profile of the experimental drug combination and to collect and assess efficacy data. Patients will be treated with concurrent everolimus and fosbretabulin for 12 weeks.

NCT ID: NCT03012789 Not yet recruiting - Clinical trials for Neuroendocrine Tumor

Surgical Intervention and the NETest

NETest_Sx
Start date: March 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the effect of different surgical resections (R0, R1, R2) on circulating NET transcripts (PCR score or NETest). A drop in circulating NET levels will be correlated with surgical excision. Secondly, variation of circulating NET transcripts will be correlated to NET recurrence to test whether this analysis may constitute an early predictive marker of disease relapse.

NCT ID: NCT03001349 Available - Clinical trials for Neuroendocrine Tumor

An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC

Start date: n/a
Phase: N/A
Study type: Expanded Access

The goal of this clinical research study is to use 68GA-DOTATOC instead of the standard-of-care 111-In-pentetreotide as a tracer chemical during PET/CT scans for diagnosing neuroendocrine tumors. A tracer is injected into participant's bloodstream to help the study doctor see possible tumors.

NCT ID: NCT02973204 Recruiting - Clinical trials for Carcinoma, Hepatocellular

Circulating Tumor Cells and Tumor DNA in HCC and NET

Start date: November 2016
Phase: N/A
Study type: Observational [Patient Registry]

Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive drugs and studies. Circulating tumor cells (CTC) has received great attention as a cancer biomarker in trying to estimate future course in patients with breast cancer, colon cancer and prostate cancer. CTC is believed to be a crucial step in cancer spreading to the bloodstream and giving rise to metastases. Detection of circulating tumor DNA (ctDNA) specifically adds specificity to the analysis of the CTC. The investigators would like to with molecular biological methods predict which patients requires special monitoring and individualized therapy and explore these tests as clinical decision support. Purpose and method In a blood sample from patients with neuro-endocrine tumor (NET) and hepatocellular carcinoma (HCC), the investigators will by cell separation, flow cytometry and DNA sequencing and digital polymerase chain reaction (PCR): 1. Identify and isolate the CTC and investigate these for tumor-specific mutations. 2. Quantify ctDNA and analyze this for specific mutations, which in the past has been found frequent in NET and HCC. 3. Compare findings of mutations on CTC and ctDNA with mutations in tissue biopsies. The results are compared with the clinical data on disease course, including the effect of treatment and survival. Subjects 40 Patients with small intestinal/unknown primary NET before treatment with somatostatin analogues 30 patients with pancreatic NET before treatment with Everolimus 30 patients with presumed radically treated HCC 30 patients with HCC in treatment with Sorafenib A blood sample will be taken prior to the start of treatment, after 1 month after start of treatment and thereafter every 3.-6. month for up to two years. Perspectives In several cancer types molecular diagnostics have had significant influence in treatment and control strategy. The goal is in future to be able to take advantage of a so-called "liquid biopsy" as clinical decision support. The study will bring new knowledge to this growing field of research.

NCT ID: NCT02955069 Not yet recruiting - Clinical trials for Non-functional Neuroendocrine Tumors of Pancreatic Origin

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin

Start date: February 2017
Phase: Phase 2
Study type: Interventional

This is a study to investigate the efficacy and safety of PDR001 in patients with advanced or metastatic non-functional neuroendocrine tumors of pancreatic, gastrointestinal (GI), or thoracic origin

NCT ID: NCT02948946 Recruiting - Clinical trials for Gastroenteropancreatic Neuroendocrine Tumor

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

Start date: January 2017
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate how well an investigational blood test performs. The study will look at the sensitivity and specificity of a blood-based multitranscriptome assay (NETest).

NCT ID: NCT02943733 Not yet recruiting - Cancer Clinical Trials

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Start date: November 2016
Phase: Phase 1
Study type: Interventional

The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug combination.

NCT ID: NCT02939651 Recruiting - Clinical trials for Neuroendocrine Tumors

A Study of Pembrolizumab in Patients With Neuroendocrine Tumors

Start date: October 2016
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test if pembrolizumab is safe and effective for treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum based chemotherapy.The study drug, pembrolizumab has been FDA approved for treating a type of skin cancer called melanoma and for metastatic non-small cell lung cancer. However, it is not approved for treatment of metastatic high-grade neuroendocrine tumors.

NCT ID: NCT02936323 Recruiting - Clinical trials for Neuroendocrine Tumors

PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers

Start date: November 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Protocol PEN-221-001 is an open-label, multicenter Phase 1/2a study evaluating PEN-221 in patients with SSTR2 expressing advanced gastroenteropancreatic (GEP) or lung or thymus or other neuroendocrine tumors or small cell lung cancer or large cell neuroendocrine carcinoma of the lung.